Search Results

Purpose: The authors investigated the potential benefit of ingesting 2 mM of quinine (bitter tastant) on a 3000-m cycling time-trial (TT) performance. Methods: Nine well-trained male cyclists (maximal aerobic power: 386 [38] W) performed a maximal incremental cycling ergometer test, three 3000-m familiarization TTs, and four 3000-m intervention TTs (∼4 min) on consecutive days. The 4 interventions were (1) 25 mL of placebo, (2) a 25-mL sweet solution, and (3) and (4) repeat 25 mL of 2-mM quinine solutions (Bitter1 and Bitter2), 30 s before each trial. Participants self-selected their gears and were only aware of distance covered. Results: Overall mean power output for the full 3000 m was similar for all 4 conditions: placebo, 348 (45) W; sweet, 355 (47) W; Bitter1, 354 (47) W; and Bitter2, 355 (48) W. However, quinine administration in Bitter1 and Bitter2 increased power output during the first kilometer by 15 ± 11 W and 21 ± 10 W (mean ± 90% confidence limits), respectively, over placebo, followed by a decay of 34 ± 32 W during Bitter1 and Bitter2 during the second kilometer. Bitter2 also induced a 11 ± 13-W increase during the first kilometer compared with the sweet condition. Conclusions: Ingesting 2 mM of quinine can improve cycling performance during the first one-third of a 3000-m TT and could be used for sporting events lasting ∼80 s to potentially improve overall performance.

Purpose: Traditional physiological testing and monitoring tools have restricted our ability to capture parameters that best relate to cycling performance under variable-intensity race demands. This study examined the validity of a 1-h variable cycling test (VCT) to discriminate between different-performance-level cyclists. Methods: Ten male national- and 13 club-level cyclists (body mass, 67 [9] and 79 [6] kg; peak power output, 359 [43] and 362 [21] W, respectively) completed a VO₂max test and two 1-h VCT protocols on 3 separate occasions. The VCT consisted of 10 × 6-min segments containing prescribed (3.5 W·kg⁻¹) and open-ended phases. The open-ended phases consisted of 4 × 30–40 s of “recovery,” 3 × 10 s at “hard” intensity, and 3 × 6-s “sprint” with a final 10-s “all-out” effort. Results: Power output for the 6- and 10-s phases was moderately higher for the national- compared with club-level cyclists (mean [SD] 10.4 [2.0] vs 8.6 [1.6] W·kg⁻¹, effect size; ±90% confidence limits = −0.87; ±0.65 and mean [SD] 7.5 [0.7] vs 6.2 [1.0] W·kg⁻¹, effect size; ±90% confidence limits = −1.24; ±0.66, respectively). Power output for the final 10-s “all-out” sprint was 15.4 (1.5) for the national- versus 13.2 (1.9) W·kg⁻¹ for club-level cyclists. Conclusion: The 1-h VCT can successfully differentiate repeat high-intensity effort performance between higher-caliber cyclists and their lower-performing counterparts.

The ingestion of quinine, a bitter tastant, improves short-term (30 s) cycling performance, but it is unclear whether this effect can be integrated into the last effort of a longer race. The purpose of this study was to determine whether midtrial quinine ingestion improves 3,000-m cycling time-trial (TT) performance. Following three familiarization TTs, 12 well-trained male cyclists (mean ± SD: mass = 76.6 ± 9.2 kg, maximal aerobic power = 390 ± 50 W, maximal oxygen uptake = 4.7 ± 0.6 L/min) performed four experimental 3,000-m TTs on consecutive days. This double-blind, crossover design study had four randomized and counterbalanced conditions: (a) Quinine 1 (25-ml solution, 2 mM of quinine); (b) Quinine 2, replicate of Quinine 1; (c) a 25-ml sweet-tasting no-carbohydrate solution (Placebo); and (d) 25 ml of water (Control) consumed at the 1,850-m point of the TT. The participants completed a series of perceptual scales at the start and completion of all TTs, and the power output was monitored continuously throughout all trials. The power output for the last 1,000 m for all four conditions was similar: mean ± SD: Quinine 1 = 360 ± 63 W, Quinine 2 = 367 ± 63 W, Placebo = 364 ± 64 W, and Control = 367 ± 58 W. There were also no differences in the 3,000-m TT power output between conditions. The small perceptual differences between trials at specific 150-m splits were not explained by quinine intake. Ingesting 2 mM of quinine during the last stage of a 3,000-m TT did not improve cycling performance.

Purpose: The risk of exercise-induced endotoxemia is increased in the heat and is primarily attributable to changes in gut permeability resulting in the translocation of lipopolysaccharides (LPS) into the circulation. The purpose of this study was to quantify the acute changes in gut permeability and LPS translocation during submaximal continuous and high-intensity interval exercise under heat stress. Methods: A total of 12 well-trained male runners (age 37 [7] y, maximal oxygen uptake [VO₂max] 61.0 [6.8] mL·min⁻¹·kg⁻¹) undertook 2 treadmill runs of 2 × 15-minutes at 60% and 75% VO₂max and up to 8 × 1-minutes at 95% VO₂max in HOT (34°C, 68% relative humidity) and COOL (18°C, 57% relative humidity) conditions. Venous blood samples were collected at the baseline, following each running intensity, and 1 hour postexercise. Blood samples were analyzed for markers of intestinal permeability (LPS, LPS binding protein, and intestinal fatty acid–binding protein). Results: The increase in LPS binding protein following each exercise intensity in the HOT condition was 4% (5.3 μg·mL⁻¹, 2.4–8.4; mean, 95% confidence interval, P < .001), 32% (4.6 μg·mL⁻¹, 1.8–7.4; P = .002), and 30% (3.0 μg·mL⁻¹, 0.03–5.9; P = .047) greater than in the COOL condition. LPS was 69% higher than baseline following running at 75% VO₂max in the HOT condition (0.2 endotoxin units·mL⁻¹, 0.1–0.4; P = .011). Intestinal fatty acid–binding protein increased 43% (2.1 ng·mL⁻¹, 0.1–4.2; P = .04) 1 hour postexercise in HOT compared with the COOL condition. Conclusions: Small increases in LPS concentration during exercise in the heat and subsequent increases in intestinal fatty acid–binding protein and LPS binding protein indicate a capacity to tolerate acute, transient intestinal disturbance in well-trained endurance runners.